Nonspecific Immunoeffector, Per Se (e.g., Adjuvant, Nonspecific Immunosti- Mulator, Nonspecific Immunopotentiator, Nonspecific Immunosuppressor, Non- Specific Immunomodulator, Etc.); Or Nonspecific Immunoeffector, Stabilizer, Emulsifier, Preservative, Carrier, Or Other Additive For A Composition Con- Taining An Immunoglobulin, An Antiserum, An Antibody, Or Fragment Thereof, An Antigen, An Epitope, Or Other Immunospecific Immunoeffector Patents (Class 424/278.1)
-
Patent number: 11834488Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.Type: GrantFiled: November 1, 2021Date of Patent: December 5, 2023Assignee: Shattuck LabsInventors: Taylor Schreiber, George Fromm, Suresh De Silva
-
Patent number: 11788053Abstract: Provided herein are compositions and methods for reducing bacterial contamination during cell culture. Such compositions and methods utilize engineered peptides or recombinant cells capable of secreting such peptides into culture medium. Also provided are methods of using the engineered peptides for inhibiting bacterial growth during culturing of cells.Type: GrantFiled: June 14, 2021Date of Patent: October 17, 2023Assignee: Melio Peptide Systems Inc.Inventors: Steve Good-Sung Wong, Hendrik Jurgens Jansen Van Vuuren
-
Patent number: 11723915Abstract: The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features: a molecular weight in the range 10-300 kDa; a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1?4)-galacturonic-alpha(1?2)-rhamnose residues; the following monosaccharide composition: 20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified; 8-50 mol. % rhamnose residues; 0-40 mol. % arabinose residues; 0-40 mol.Type: GrantFiled: April 22, 2020Date of Patent: August 15, 2023Assignee: NutriLeads B.V.Inventors: Ruud Albers, Maria Tzoumaki
-
Patent number: 11712439Abstract: This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT inhibitors are provided.Type: GrantFiled: August 9, 2018Date of Patent: August 1, 2023Assignees: Mayo Foundation for Medical Education and Research, Shanghai Changhai HospitalInventors: Haojie Huang, Yinghao Sun, Shancheng Ren
-
Patent number: 11696950Abstract: Described herein are dry vaccine compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry vaccine can be readily reconstituted to form a stable liquid vaccine without significant loss of activity.Type: GrantFiled: October 10, 2018Date of Patent: July 11, 2023Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Zhengrong Cui, Robert O. Williams, III, Xinran Li
-
Patent number: 11638726Abstract: Disclosed are probiotic formulations comprising fortified avian eggs and avian egg products such as egg powder, and methods for producing the same substantially no meat containing growth media such as MRS. The formulations may be used to supplement food that include, but are not limited to, baby foods, milk, and pet foods. Effective amounts of the fortified egg formulations comprising at least about 109 CFU/dosage of probiotics may be used to treat health issues that include, but are not limited to, irritable bowel syndrome. The probiotic formulation may comprise bacterial strains comprising at least one of L. casei, L. rhamnosus, B. breve, Bifidobacterium longum, L. acidophilus, L. plantarum, B. bifidum, L. fermentum, L. lactis, L. paracasei, and L. salivarius.Type: GrantFiled: September 25, 2020Date of Patent: May 2, 2023Assignee: TALL GOODS LLCInventor: Andrea Romero
-
Patent number: 11638754Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: GrantFiled: February 9, 2021Date of Patent: May 2, 2023Assignee: Merck Sharp & Dohme LLCInventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
-
Patent number: 11617729Abstract: The uses of guanidine hydrochloride as a drug for treating cancers/tumors. Guanidine hydrochloride can destroy the formation of hydrogen bonds by polar molecules on the surface of cancer cells and the macromolecules taken up, thereby demonstrating that guanidine hydrochloride can inhibit the uptake by cancer cells. The present invention provides new uses of guanidine hydrochloride in the treatment of subjects suffering from cancers/tumors and prevention of recurrence after cancer operation. The dose of guanidine hydrochloride administration is 10-35 mg/kg a day. The hydrochloride dose of the guanidine has a significant inhibitory effect on the uptake of DNA by cancer cells, which in turn can effectively inhibit the proliferation of cancer cells; besides, the inhibition rate of liver cancer tumors 9 days after the injection of guanidine hydrochloride drugs can reach 42%, and the inhibition rate of lung cancer tumors 7 days after the injection of guanidine hydrochloride drugs reach 56.8%.Type: GrantFiled: July 9, 2020Date of Patent: April 4, 2023Inventors: Yanping Kong, Jinhong Liu
-
Patent number: 11612644Abstract: The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c (BDCA-1)+/CD19? dendritic cells, wherein CD1c(BDCA-1)+/CD19? dendritic cells are depleted for CD1c (BDCA-1)+/CD19?/CD14+ cells.Type: GrantFiled: July 22, 2020Date of Patent: March 28, 2023Assignee: MILTENYI BIOTEC B.V. & CO. KGInventors: Jolanda De Vries, Carl Figdor, Ghaith Bakdash
-
Patent number: 11611236Abstract: A self-capacitance based remote power delivery device includes a power source, an energy harvesting device, and a substrate. The power source and the energy harvesting device are configured to be capacitively coupled to a self-capacitive body. The substrate is configured to be capacitively coupled to a portion of the self-capacitive body in contact with the substrate.Type: GrantFiled: August 6, 2021Date of Patent: March 21, 2023Assignee: Washington UniversityInventors: Shantanu Chakrabartty, Yarub Alazzawi, Kenji Aono, Erica L. Scheller
-
Patent number: 11576975Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).Type: GrantFiled: September 21, 2020Date of Patent: February 14, 2023Assignee: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATIONInventors: Warren O. Haggard, Scott P. Noel, Joel D. Bumgardner
-
Patent number: 11564995Abstract: Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of ?-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and methods of making the nanoparticle system. Further included are immunotherapy methods including administering the nanoparticle system to a subject in need thereof, such as a human cancer patient.Type: GrantFiled: October 29, 2020Date of Patent: January 31, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Seungpyo Hong, Woo-jin Jeong
-
Patent number: 11547672Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.Type: GrantFiled: July 12, 2019Date of Patent: January 10, 2023Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, LA JOLLA INSTITUTE FOR IMMUNOLOGYInventors: Darrell J. Irvine, Murillo Silva, Shane Crotty, Yu Kato
-
Patent number: 11479823Abstract: Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.Type: GrantFiled: October 23, 2020Date of Patent: October 25, 2022Assignee: Exact Sciences CorporationInventors: Hatim Allawi, Graham P. Lidgard, Chateen Krueger, Michael W. Kaiser, Tamara J. Sander
-
Patent number: 11447550Abstract: This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1 binding molecule with advantages over current antibody technologies for detecting PD-L1.Type: GrantFiled: September 27, 2017Date of Patent: September 20, 2022Assignee: The Curators of the University of MissouriInventors: Raghuraman Kannan, Charles Caldwell, Jr., Vitukudi Narayanaiyengar Balaji, Govardhan Aadharsh Balaji
-
Patent number: 11446227Abstract: The present invention provides a method for preparing an high internal phase of pumpkin seed protein nanoparticles, including dissolving pumpkin seed protein powder in water and adjusting pH to approximately 8 to 11 to obtain a pumpkin seed protein solution; adding the pumpkin seed protein solution through a peristaltic pump into an ethanol solution with stirring for 4 hours to obtain a first solution; performing a centrifugation to the first solution and collecting precipitates; diluting the precipitates with water and performing a freeze-drying to obtain the pumpkin seed protein nanoparticles. The present invention first uses an anti-solvent method to prepare pumpkin seed protein nanoparticles, which have excellent emulsifying properties and can stabilize the high internal phase emulsion. In addition, the resulting pumpkin seed protein nanoparticles can stabilize the high internal phase emulsion independently without compounding with other substances.Type: GrantFiled: December 2, 2020Date of Patent: September 20, 2022Assignee: Jiangnan UniversityInventors: Jing Wang, Yongqiang Shen, Cheng Yang, Guangqun Cao
-
Patent number: 11406693Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.Type: GrantFiled: March 12, 2018Date of Patent: August 9, 2022Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
-
Patent number: 11358988Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: December 11, 2019Date of Patent: June 14, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: 11344631Abstract: The present invention refers to nucleotide sequences used for driving the expression of a therapeutic gene, preferably FVIII and/or its variants specifically in endothelial cells and/or hematopoietic, preferably myeloid cells. The sequences are useful for gene and/or cell therapy, preferably for treating hemophilia, more preferably type A hemophilia.Type: GrantFiled: June 12, 2017Date of Patent: May 31, 2022Assignee: Universita' del Piemonte OrientaleInventors: Antonia Follenzi, Diego Zanolini, Rosella Fama', Simone Merlin
-
Patent number: 11318200Abstract: The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided.Type: GrantFiled: November 21, 2014Date of Patent: May 3, 2022Assignee: Zoetis Services LLCInventors: Paul Joseph Dominowski, Duncan Mwangi, Joseph M. Bricker, Dennis L. Foss, Sharath K. Rai, Suman Mahan
-
Patent number: 11319343Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.Type: GrantFiled: June 29, 2018Date of Patent: May 3, 2022Assignees: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY, UNIVERSITY OF SOUTH AUSTRALIA, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEEN ELIZABETH NEAR DUBLIN, MONASH UNIVERSITYInventors: Stavros Selemidis, Doug A. Brooks, John O'Leary
-
Patent number: 11278604Abstract: A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.Type: GrantFiled: March 26, 2018Date of Patent: March 22, 2022Assignee: President and Fellows of Harvard CollegeInventors: Jaeyun Kim, Weiwei Aileen Li, David J. Mooney
-
Patent number: 11278612Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.Type: GrantFiled: March 19, 2019Date of Patent: March 22, 2022Assignee: Novavax, Inc.Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
-
Patent number: 11266602Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.Type: GrantFiled: May 15, 2017Date of Patent: March 8, 2022Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Christopher B. Fox, Susan S. Lin, Darrick Carter, Neal Van Hoeven, Mayuresh M. Abhyankar, William A. Petri
-
Patent number: 11149066Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.Type: GrantFiled: September 13, 2017Date of Patent: October 19, 2021Assignees: DAIICHI SANKYO COMPANY, LIMITED, PEPTIDREAM INC.Inventors: Takahiro Yamaguchi, Yutaka Mori, Hironao Saito, Hideki Kubota, Akihiro Furukawa, Eri Otsuka, Yutaka Ishigai, Hiroshi Ijiri, Patrick Reid
-
Patent number: 11103605Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.Type: GrantFiled: May 17, 2017Date of Patent: August 31, 2021Assignee: Bristol-Myers Squibb CompanyInventors: David J. Donnelly, Kenneth M. Boy, Yunhui Zhang, Joonyoung Kim, Adrienne Pena
-
Patent number: 11077045Abstract: Methods of using Shilajit or its individual components, or a combination of two or more of these components, to improve skin microperfusion, to upregulate ECM related genes in the skin, to increase endothelial cell migration and growth of blood vessels, and thus to improve skin health are presented herein.Type: GrantFiled: June 26, 2018Date of Patent: August 3, 2021Assignee: Natreon, Inc.Inventors: Chandan K. Sen, Sanyasi R. Kalidindi
-
Patent number: 11073509Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.Type: GrantFiled: June 10, 2016Date of Patent: July 27, 2021Assignee: Celcuity Inc.Inventors: Lance Gavin Laing, Brian Francis Sullivan
-
Patent number: 11071753Abstract: Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.Type: GrantFiled: December 2, 2019Date of Patent: July 27, 2021Assignee: University of South CarolinaInventor: Daping Fan
-
Patent number: 11053297Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+ GR1? (Ly6C?)) monocytes; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.Type: GrantFiled: October 27, 2016Date of Patent: July 6, 2021Assignee: La Jolla Institute for Allergy and ImmunologyInventors: Catherine C. Hedrick, Richard Hanna
-
Patent number: 11040107Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.Type: GrantFiled: April 9, 2018Date of Patent: June 22, 2021Assignee: Apellis Pharmaceuticals, Inc.Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
-
Patent number: 10993980Abstract: Present disclosure provides a pharmaceutical composition or a preparation composition containing fermented papaya preparation as an active ingredient for treating a patient with electrohypersensitivity or relieving a symptom thought to be a symptom of the electrohypersensitivity, and methods of use thereof.Type: GrantFiled: August 27, 2019Date of Patent: May 4, 2021Assignee: Osato International Inc.Inventors: Yukiyasu Hayashi, Dominique Belpomme
-
Patent number: 10925880Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib.Type: GrantFiled: September 15, 2017Date of Patent: February 23, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventor: Martin Lange
-
Patent number: 10925944Abstract: The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c(BDCA-1)+/CD19? dendritic cells, wherein CD1c(BDCA-1)+/CD19? dendritic cells are depleted for CD1c(BDCA-1)+/CD19?/CD14+ cells.Type: GrantFiled: September 10, 2015Date of Patent: February 23, 2021Assignee: MILTENYI BIOTEC B.V. & CO. KGInventors: Jolanda De Vries, Carl Figdor, Ghaith Bakdash
-
Patent number: 10799592Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).Type: GrantFiled: July 31, 2018Date of Patent: October 13, 2020Assignee: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATIONInventors: Warren O. Haggard, Scott P. Noel, Joel D. Bumgardner
-
Patent number: 10782300Abstract: The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.Type: GrantFiled: December 24, 2013Date of Patent: September 22, 2020Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, F. Hoffmann-La Roche AGInventors: Toshihiko Ohtomo, Ya-Chi Chen, Jun Amano, Mikiko Nakamura
-
Patent number: 10718755Abstract: A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing N-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.Type: GrantFiled: November 24, 2017Date of Patent: July 21, 2020Assignee: WUHAN UNIVERSITYInventor: Hongliang Li
-
Patent number: 10639367Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides compositions (e.g., vaccines) and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against cancer (e.g., a tumor) or against any type of antigen (e.g. bacterial, viral, parasite-derived)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. prophylactic, therapeutic and preventive medicine (e.g., vaccination)) and research applications. It particularly relates to the area of active specific immunotherapy of cancer (“cancer vaccines”), and provides procedures for the preparation of therapeutic vaccines that can eliminate cancer cells.Type: GrantFiled: November 1, 2013Date of Patent: May 5, 2020Assignee: CYTUVAXInventor: Frank Walter Falkenberg
-
Patent number: 10583178Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.Type: GrantFiled: August 23, 2016Date of Patent: March 10, 2020Assignee: NUTRAMAX LABORATORIES, INC.Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
-
Patent number: 10561686Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.Type: GrantFiled: September 28, 2018Date of Patent: February 18, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
-
Patent number: 10544088Abstract: The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.Type: GrantFiled: December 1, 2017Date of Patent: January 28, 2020Assignee: DS Biopharma LimitedInventors: Mehar Manku, David Coughlan, Bill Downes
-
Patent number: 10543168Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.Type: GrantFiled: April 24, 2017Date of Patent: January 28, 2020Assignee: Ara Medical, LLCInventors: Donald J. Eaton, Bin Huang, Michael A. Savitt
-
Patent number: 10543248Abstract: The present invention relates to a pharmaceutical composition, which comprises a Stemonae Radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke, a method for preventing or treating the occurrence of inflammatory bowel diseases using the composition, a method for suppressing the expression of inflammatory cytokines using the composition, and to a food composition, which comprises the Stemonae Radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke.Type: GrantFiled: July 3, 2013Date of Patent: January 28, 2020Assignee: University-Industry Cooperation Group of Kyung Hee UniversityInventors: Jin Ju Kim, Eun Jung Ko, Eui Jeoung Lee
-
Patent number: 10537625Abstract: Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.Type: GrantFiled: April 3, 2017Date of Patent: January 21, 2020Assignee: University of South CarolinaInventor: Daping Fan
-
Patent number: 10508069Abstract: The invention provides a method for preparing a carboxylic acid, which method includes the steps of providing magnesium carboxylate, wherein the carboxylic acid corresponding with the carboxylate has a solubility in water at 20° C. of 80 g/100 g water or less; acidifying the magnesium carboxylate with HCl, thereby obtaining a solution comprising carboxylic acid and magnesium chloride (MgCl2); optionally a concentration step, wherein the solution comprising carboxylic acid and MgCl2 is concentrated; precipitating the carboxylic acid from the solution comprising the carboxylic acid and MgCl2, thereby obtaining a carboxylic acid precipitate and a MgCl2 solution.Type: GrantFiled: July 9, 2018Date of Patent: December 17, 2019Assignee: PURAC BIOCHEM B.V.Inventors: André Banier De Haan, Jan Van Breugel, Paulus Loduvicus Johannes Van Der Weide, Peter Paul Jansen, José Maria Vidal Lancis, Agustin Cerdà Baró
-
Patent number: 10456427Abstract: Lobster hemolymph and compositions derived therefrom for the prevention or treatment of viral diseases or cancer by systemic administration.Type: GrantFiled: June 8, 2016Date of Patent: October 29, 2019Assignee: Lobster Unlimited LLCInventor: Robert C. Bayer
-
Patent number: 10456459Abstract: The invention provides a liposomal adjuvant composition comprising an external membrane and an internal compartment, the external membrane comprising: a quaternary ammonium compound; a sterol; a phospholipid; and a glycolipid. Vaccine compositions comprising the liposomal adjuvant of the instant invention are also provided.Type: GrantFiled: July 19, 2016Date of Patent: October 29, 2019Assignee: Zoetis Services LLCInventors: Paul Joseph Dominowski, Duncan Mwangi, Sharath K. Rai, Dennis L. Foss, Traci K. Godbee, Laurel Mary Sly, Suman Mahan, Shaunak Vora
-
Patent number: 10434142Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.Type: GrantFiled: December 22, 2017Date of Patent: October 8, 2019Assignee: Chan Soon-Shiong Nanthealth FoundationInventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
-
Patent number: 10398767Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.Type: GrantFiled: February 14, 2018Date of Patent: September 3, 2019Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
-
Patent number: 10365272Abstract: The present disclosure relates to the field of immunoassays for Gram negative bacteria, in particular N. meningitidis. The disclosure provides a simple and affordable immunoassay to quantitate polysaccharides in meningococcal vaccines for the evaluation of antigen content and lot-to-lot manufacturing consistency. The inventors have found a Sandwich ELISA that can be applicable for the quantitation and identification of N. meningitidis serogroup X polysaccharide in a multivalent meningococcal polysaccharide-protein conjugate vaccine as well as in a multivalent meningococcal plain polysaccharide vaccine. Said assay employs a polyclonal antibody as capture antibody and a novel monoclonal antibody against serogroup X polysaccharide as detection antibody. Further the assay is rapid, robust and reproducible.Type: GrantFiled: July 24, 2015Date of Patent: July 30, 2019Assignee: SERUM INSTITUTE OF INDIA PRIVATE LIMITEDInventors: Kale Sameer Manohar, Sharma Pankaj Keshav, Gairola Sunil Jagdishprasad